
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare has demonstrated a stabilization in gross margin at 20.0%, consistent with the previous quarter and exceeding expectations. The recent acquisition agreement with Aya Healthcare for $18.61 per share indicates a significant 67% premium over the stock's closing price prior to the announcement, reflecting strong investor confidence in the company's value. The adjusted timeline for the acquisition's completion to the second half of 2025 suggests a strategic approach to ensure a smooth transition, potentially benefiting stakeholders in the long term.
Bears say
Cross Country Healthcare's Q1/25 financial performance indicates significant challenges, with a 44% year-over-year decline in adjusted EBITDA to $8.6 million, despite exceeding expectations in a revenue shortfall context. The company's revenue also dropped 23% year-over-year to $293.4 million, falling short of both internal estimates and market consensus, largely reflecting ongoing softer demand conditions in the healthcare travel staffing sector. Furthermore, the downward revision of the 2025 revenue estimate to $1.166 billion, a reduction of 13.3% year-over-year from previous projections, underscores the ongoing adverse market dynamics affecting the company.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares